Abstract:Objectives Due to increased gene dose for the amyloid precursor protein (APP), elderly adults with Down syndrome (DS) are at a markedly increased risk of Alzheimer's disease (AD), known as DS‐AD. How the increased APP gene dose acts and which APP products are responsible for DS‐AD is not well understood, thus limiting strategies to target pathogenesis. As one approach to address this question, we used a novel class of γ‐secretase modulators that promote γ‐site cleavages by the γ‐secretase complex, resulting in lower levels of the Aβ42 and Aβ40 peptides. Methods Ts65Dn mice, which serve as a model of DS, were treated via oral gavage with 10 mg/kg/weekday of BPN15606 (a potent and novel pyridazine‐containing γ‐secretase modulators). Treatment started at 3 months‐of‐age and lasted for 4 months. Results Demonstrating successful target engagement, treatment with BPN15606 significantly decreased levels of Aβ40 and Aβ42 in the cortex and hippocampus; it had no effect on full‐length APP or its C‐terminal fragments in either 2 N or Ts65Dn mice. Importantly, the levels of total amyloid‐β were not impacted, pointing to BPN15606‐mediated enhancement of processivity of γ‐secretase. Additionally, BPN15606 rescued hyperactivation of Rab5, a protein responsible for regulating endosome function, and normalized neurotrophin signaling deficits. BPN15606 treatment also normalized the levels of synaptic proteins and tau phosphorylation, while reducing astrocytosis and microgliosis, and countering cognitive deficits. Interpretation Our findings point to the involvement of increased levels of Aβ42 and/or Aβ40 in contributing to several molecular and cognitive traits associated with DS‐AD. They speak to increased dosage of the APP gene acting through heightened levels of Aβ42 and/or Aβ40 as supporting pathogenesis. These findings further the interest in the potential use of γ‐secretase modulators for treating and possibly preventing AD in individuals with DS. ANN NEUROL 2024

Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene dose

Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP

Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein

Common genetic signatures of Alzheimer's disease in Down Syndrome

A Novel Mechanism Underlying Pathogenesis of Down Syndrome

A Common Link Between Alzheimer's Disease and Down Syndrome

Amyloid Precursor Protein-Mediated Endocytic Pathway Disruption Induces Axonal Dysfunction and Neurodegeneration.

APP and DYRK1A regulate axonal and synaptic vesicle protein networks and mediate Alzheimer's pathology in trisomy 21 neurons

Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome.

P4-064 Increased BACE1 Maturation in Down Syndrome

Amyloid-β Precursor Protein Facilitates the Regulator of Calcineurin 1-Mediated Apoptosis by Downregulating Proteasome Subunit Α Type-5 and Proteasome Subunit Β Type-7.

Exosomal biomarkers in Down syndrome and Alzheimer's disease

Reduced synaptic vesicle density and active zone size in mice lacking amyloid precursor protein (APP) and APP-like protein 2.

APP antisense oligonucleotides reduce Aβ aggregation and rescue endolysosomal dysfunction in Alzheimer's disease

γ‐Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer‐Related Pathologies in a Mouse Model of Down Syndrome

Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer's Disease Associated with Down Syndrome

Alzheimer’s drugs, APPlication for Down syndrome?

Nanoscale Reorganisation of Synaptic Proteins in Alzheimer's Disease

Discrepancy of synaptic and microtubular protein phosphorylation in the hippocampus of APP/PS1 and MAPT×P301S transgenic mice at the early stage of Alzheimer's disease

Sorting Nexin 27 Regulates Aβ Production Through Modulating Γ-Secretase Activity

Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2.